secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2026-08-06T20:30:48+00:00
Accession:  0001104659-26-092064
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport Q2 2026 revenue $49.0M (+8% YoY); achieves positive adjusted EBITDA
----------------------------------------------------------------------------

- Revenue $49.0M, up 8% YoY; Life Sciences Services +15%, BioStorage/BioServices +25%.
- Adjusted EBITDA from continuing operations positive $0.4M vs -$0.9M in Q2 2025.
- Net loss attributable to common stockholders $0.20 per share (vs $2.13 income in Q2 2025, which included divestiture gain).
- Supporting 779 clinical trials and 22 commercial CGT as of June 30, 2026.
- Cash and short-term investments $396.7M; anticipate 11 possible BLA/MAA applications in H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465926092064/0001104659-26-092064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465926092064/tm2622464d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-092064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer